• Organizations: SpyGlass Pharma, Inc
Leadership watch: SpyGlass, Lumata Health, and Horizon Surgical report changes
Business

Leadership watch: SpyGlass, Lumata Health, and Horizon Surgical report changes

Latest news from the eyecare space includes a new VP at SpyGlass ahead of phase 3 trials on its glaucoma drug delivery platform.
SpyGlass Pharma raises $75M to advance sustained-release drug delivery platform
Pipeline

SpyGlass Pharma raises $75M to advance sustained-release drug delivery platform

Financing to support upcoming phase 3 trials on the company’s long-term delivery system of bimatoprost for glaucoma and OHT treatment.
SpyGlass Pharma reports positive 18-month data on glaucoma sustained delivery system
Research

SpyGlass Pharma reports positive 18-month data on glaucoma sustained delivery system

Presented at ASCRS, new findings show promising visual outcomes and IOP lowering following sustained-release delivery of bimatoprost.
SpyGlass Pharma secures $90M in financing for chronic ophthalmic disease drug delivery platform
Business

SpyGlass Pharma secures $90M in financing for chronic ophthalmic disease drug delivery platform

First-of-its-kind controlled-release platform is designed to significantly lower IOP.
SpyGlass Pharma releases 6-month data from first-in-human trial for glaucoma
Pipeline

SpyGlass Pharma releases 6-month data from first-in-human trial for glaucoma

Breakthrough drug delivery platform demonstrates significant IOP lowering.